FDA seeks treatment protocol for Protalix Gaucher's disease drug

07/6/2009 | Wall Street Journal, The

The FDA asked Protalix to submit a treatment protocol for prGCD, its experimental Gaucher's disease drug, in light of a manufacturing problem that is expected to reduce the supply of Genzyme's Cerezyme. Protalix and the agency are reportedly discussing parameters to increase patients' access to prGCD.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX